The identification of chemotherapeutic drugs against Novel Coronavirus (2019-nCoV) is a significant requirement due to the rapid rise in deaths due to Corona Viral Infection all around the world. Therefore, it is of interest to document the molecular docking analysis data of 32 N-substituted Oseltamivir derivatives inhibitors of influenza virus H5N1 with the Novel Coronavirus main protease (2019-nCoV). We describe the optimal binding features of Oseltamivir derivatives with the SARS-Cov-2 main protease (Code PDB: 6LU7) for further consideration.
All Keywords
【저자키워드】 COVID-19, SARS-CoV-2, coronavirus, oseltamivir, molecular docking, H5N1, 【초록키워드】 2019-nCoV, protease, Corona, death, novel, inhibitor, binding, 6LU7, code, molecular docking analysis, derivative, feature, chemotherapeutic drug, influenza virus H5N1, 【제목키워드】 docking, protease, Analysis, derivative, the SARS-CoV-2,
【저자키워드】 COVID-19, SARS-CoV-2, coronavirus, oseltamivir, molecular docking, H5N1, 【초록키워드】 2019-nCoV, protease, Corona, death, novel, inhibitor, binding, 6LU7, code, molecular docking analysis, derivative, feature, chemotherapeutic drug, influenza virus H5N1, 【제목키워드】 docking, protease, Analysis, derivative, the SARS-CoV-2,